Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Renal Insufficiency, Chronic Clinical Trial

— FRONTIER  

Official title:

Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Effect of Ferric Citrate on Time to a Composite Endpoint of Initiation of Maintenance Dialysis or All-cause Mortality vs Placebo in Adults With Advanced CKD

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05085275
• Other study ID #: USRC-2021-002
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: March 30, 2022
• Est. completion date: August 2024

Study information

• Verified date: October 2023
• Source: USRC Kidney Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A 9-month randomized, double-blind, placebo-controlled study to compare the effect of fixed dose ferric citrate versus placebo in patients with advanced chronic kidney disease (eGFR ≤20 ml/min/1.73m2) on the composite endpoint of time to initiation of maintenance dialysis or all-cause mortality.

Description:

This multicenter, randomized, double-blind, placebo-controlled clinical trial is being conducted to determine the effect of ferric citrate on the time to a composite endpoint of initiation of maintenance dialysis or all-cause mortality in patients with non-dialysis dependent, advanced CKD. Up to 400 subjects will be randomized in 1:1 ratio to receive either ferric citrate or matching placebo. All subjects will initiate dosing at 2 tablets per meal or snacks, up to 3 times per day (maximum of 6 tablets per day). The dose of ferric citrate/placebo will only be adjusted based on safety and/or tolerability. Given the double-blind design of this trial, investigators will be instructed to not prescribe commercial Auryxia to either study arm. Study visits during the treatment period are to be conducted as part of routine scheduled clinical encounters. Standard of care local laboratory results will be collected however no study specific laboratory tests other than a pregnancy test in women of child-bearing potential will be required.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 400
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult patients greater or equal to 18 years old.

2. Diagnosis of NDD advanced CKD, regardless of etiology. Advanced CKD is defined as at least one local laboratory determined estimated glomerular filtration rate (eGFR) =20 ml/min/1.73m2 (calculated per any commonly used method or equation for estimating eGFR) within 90 days of Day 1.

3. Most recent transferrin saturation (TSAT) less than or equal to 45% within 45 days of Day 1.

4. Most recent serum phosphate is greater or equal to 3.0 mg per dL within 45 days of Day 1.

5. Most recent ferritin is less than or equal to 500 ng per mL within 45 days of Day 1.

6. Women of child-bearing potential must have a negative serum or urine pregnancy test within 28 days prior to Day 1.

7. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure.

Exclusion Criteria:

1. Patients who, in the opinion of the Investigator, have acute kidney injury rather than CKD.

2. Patients with planned/imminent maintenance dialysis, or that are anticipated to begin maintenance dialysis within 8 weeks from Screening, in the opinion of the Investigator.

3. A known allergy or intolerance to ferric citrate or any of its constituents.

4. Hypersensitivity reaction to previous oral iron therapy.

5. History of hemochromatosis or iron overload syndrome (e.g., hereditary sideroblastic anemia, thalassemia, polycythemia vera).

6. Active malignancy requiring current treatment except for non-melanoma skin cancer regardless of treatment.

7. Active drug or alcohol dependence or abuse (excluding tobacco use or use of medical or recreational marijuana) within the 12 months prior to Screening or evidence of such abuse, in the opinion of the Investigator.

8. Limited life expectancy (less than 6 months) in the opinion of the Investigator.

9. Females who are known to be pregnant or are breast-feeding during Screening or are planning to become pregnant and breastfeeding during the study period.

10. Evidence of a clinically active infection requiring antibiotics at Randomization.

11. Unable to comply with study requirements or in the opinion of the Investigator, not clinically stable to participate in the study.

12. Use of an investigational medication or participation in an investigational study within 30 days prior to Day 1.

13. Patients with a scheduled date for receipt of living donor kidney transplant

Related Conditions & MeSH terms

• Anemia
• Anemia, Iron Deficiency
• Anemia, Iron-Deficiency
• Cardiovascular
• Disease Progression
• Hyperphosphatemia
• Iron
• Renal Anemia
• Renal Insufficiency
• Renal Insufficiency, Chronic

Intervention

Drug:
• Ferric Citrate 1 GM Oral Tablet [AURYXIA]
All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
• Placebo
All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.

Locations

Country	Name	City	State
United States	Dialysis Clinic, Inc.	Albany	Georgia
United States	Nephrology Associates of Western NY	Amherst	New York
United States	Balboa Research SMO	Chula Vista	California
United States	Nephrology and Hypertension Specialists, PC	Dalton	Georgia
United States	Balboa Research SMO	El Centro	California
United States	Balboa Research SMO	Escondido	California
United States	Associates in Nephrology	Fort Myers	Florida
United States	High Desert Nephrology Associates	Gallup	New Mexico
United States	Kidney Associates of Kansas City	Kansas City	Missouri
United States	Dialysis Clinic, Inc.	Knoxville	Tennessee
United States	Balboa Research SMO	La Mesa	California
United States	South Texas Renal Care Group	Live Oak	Texas
United States	Rocky Mountain Kidney Care	Lone Tree	Colorado
United States	Arkansas Nephrology & Hypertension Clinic	Pine Bluff	Arkansas
United States	Nephrology-Hypertension Associates of Central NJ	S. River	New Jersey
United States	Clinical Advancement Center, PLLC	San Antonio	Texas
United States	South Texas Renal Care Group	San Antonio	Texas
United States	South Texas Renal Care Group	San Antonio	Texas
United States	South Texas Renal Care Group	San Antonio	Texas
United States	South Texas Renal Care Group	San Antonio	Texas
United States	Balboa Research SMO - Kearney Mesa	San Diego	California
United States	Major Health Partners	Shelbyville	Indiana
United States	Spartanburg Nephrology Associates	Spartanburg	South Carolina

Sponsors (2)

Lead Sponsor	Collaborator
USRC Kidney Research	Akebia Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to a composite endpoint of initiation of maintenance dialysis or all-cause mortality	Time to a composite endpoint of initiation of maintenance dialysis or all-cause mortality	9 months
Secondary	Time to first hospitalization event reported as a serious adverse event (SAE) (excluding disease-related hospitalization [e.g., dialysis access placement, dialysis initiation, kidney transplant] and elective procedures)	Time to first hospitalization event reported as a serious adverse event (SAE) (excluding disease-related hospitalization [e.g., dialysis access placement, dialysis initiation, kidney transplant] and elective procedures)	9 months
Secondary	Component of Primary - Time to Initiation of Maintenance Dialysis	Component of Primary - Time to Initiation of Maintenance Dialysis	9 months
Secondary	Component of Primary - Time to All-Cause Mortality	Component of Primary - Time to All-Cause Mortality	9 months